AI & Diagnostics Software in Florida

Focalyx is a MedTech company specializing in precision diagnosis and treatment of prostate cancer through AI-driven software and minimally invasive procedural guidance. The Focalyx Fusion platform provides computer-assisted surgical planning and real-time intraoperative guidance for focal prostate therapy, enabling targeted ablation of cancerous lesions while preserving healthy prostate tissue and function. The platform combines advanced imaging analysis with GPS-like navigation to deliver office-based, outpatient prostate cancer treatment with minimal hospitalization, fast recovery, and improved preservation of urinary and sexual function. Clinical outcomes demonstrate 86% cancer-free status at 5 years with 95% urinary improvement and 88% erectile retention rates across 6,000+ procedures performed globally.

Sun Nuclear Corporation is a global leader in radiation oncology quality assurance (QA) solutions, serving over 6,000 healthcare facilities in more than 130 countries. Founded in 1984 and headquartered in Melbourne, Florida, the company specializes in comprehensive QA platforms for radiation therapy and diagnostic imaging, with solutions deployed in over 90% of U.S. cancer treatment centers and 60% of global facilities. Sun Nuclear provides advanced dosimetry verification, machine QA, patient-specific plan verification, and AI-powered treatment planning tools. The portfolio includes proprietary detector technologies, phantom systems, and integrated software solutions designed to enhance patient safety and streamline clinical workflows. In 2021, Sun Nuclear was acquired by Mirion Technologies, strengthening its position in radiation safety innovation. The company offers extensive clinical support, training, and service backed by over 300 years of combined team expertise and 34 patents in radiation oncology and diagnostic imaging QA.

Nuvo Cares is a healthcare company headquartered in Aventura, Florida, specializing in remote pregnancy monitoring and maternal-fetal health management. Founded in 2007 and publicly traded on NASDAQ since 2024, the company offers INVU by Nuvo™, the first FDA-cleared self-administered remote pregnancy monitoring system. The platform combines wearable sensors with a mobile application to enable physician-prescribed remote non-stress testing and continuous monitoring of fetal heart rate, maternal heart rate, and uterine contractions from home. The system processes vital health signals via cloud-based technology using advanced ECG and PCG sensors integrated with artificial intelligence and machine learning algorithms. INVU serves pregnant mothers, clinicians, and healthcare payers, addressing access barriers in prenatal care and improving maternal-fetal health outcomes. The company's clinical validation includes publications in the American Journal of Obstetrics and Gynecology (AJOG) demonstrating real-world effectiveness in high-risk pregnancies.

Neuro Rehab Recovery Technologies is a clinical solutions developer and distributor specializing in advanced neurorehabilitation equipment and systems. The company operates across North America, with primary headquarters in the USA and distribution presence in Canada, Mexico, Bolivia, Colombia, and Costa Rica. The organization markets itself as clinician-owned and operated, providing a comprehensive portfolio of technologies for neurological injuries and diseases including stroke, cerebral palsy, spinal cord injury, and traumatic brain injury. Product portfolio includes robotic rehabilitation systems (exoskeletons: Keeogo, ExoAtlet EA2), hand rehabilitation devices (SYREBO hand robots, G1 robotic glove, H2 system), functional electrical stimulation systems (G4 FES Foot Drop System), active-passive therapy systems (MOTOmed series for upper and lower extremity), gait training treadmills (AeroRunner anti-gravity system), mirror therapy systems (Syrebo Smart Rehabilitation Mirror), dynamic arm support systems, and VR-based balance assessment and training platforms (UprightVR). The company also distributes the Neuro20 Smart stimulation device and percussive massage equipment. Neuro Rehab Recovery positions itself as a clinical education and training partner rather than a treatment clinic, emphasizing comprehensive training, clinical support, and evidence-based outcomes. The company serves clinics, rehabilitation facilities, hospitals, and individual patients. Major institutional partners include Cleveland Clinic, NewYork-Presbyterian, NYU, CHOP, Northwell Health, and numerous orthotics and prosthetics centers. The organization distributes technologies from multiple global manufacturers and maintains an e-commerce platform for direct consumer sales. No specific FDA clearances or certifications are mentioned on the primary website content provided.

Vycor Medical, Inc. operates two distinct business units specializing in neurosurgical and neurotherapeutic solutions. The primary division designs and manufactures neurosurgical medical devices, with the ViewSite Brain Access System (VBAS) as the flagship product—a minimally invasive neurosurgical device that improves access to brain lesions while reducing tissue damage. Clinical evidence from over 50 studies demonstrates VBAS results in reduced brain tissue trauma, minimized invasiveness, improved surgical visibility, and shortened operating and recovery times. The company's secondary business unit, NovaVision, develops non-invasive, computer-based vision rehabilitation therapies for patients with vision loss resulting from neurological trauma such as stroke. NovaVision Visual Restoration Therapy (VRT) is the only FDA-cleared therapy for vision rehabilitation following neurological brain damage; it is complemented by the NeuroEyeCoach program, which trains patients to make improved eye movements to enhance visual field detection. Vycor Medical serves neurosurgeons, neurologists, rehabilitation specialists, and vision care providers across hospital and outpatient settings. The company holds FDA regulatory clearance for its therapeutic products and demonstrates commitment to clinical validation and evidence-based outcomes.

Vassol, Inc. develops NOVA (Noninvasive Optimal Vessel Analysis), an advanced 3D blood flow analytics and imaging software platform for quantitative hemodynamic analysis of cerebral vasculature. NOVA integrates with standard MRI systems—specifically Time-of-Flight MRA and 2D phase-contrast magnetic resonance imaging—to generate three-dimensional vascular models and quantify intracranial blood flow without contrast agents or radiation exposure. The platform is vendor-neutral, PACS-compatible, and features automated processing with patented algorithms for perpendicular scan plane prescription. Clinically validated over 20+ years, NOVA serves neuroradiologists and stroke specialists for diagnosis, treatment planning, and post-intervention assessment of cerebrovascular conditions including carotid stenosis, vertebrobasilar disease, arterial dissection, aneurysm management, and moyamoya disease. An NIH study demonstrated NOVA qMRA® as a robust, independent predictor of recurrent stroke risk.